Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBSNASDAQ:IRWDNASDAQ:RIGLNASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent BioSolutions$6.40-1.5%$5.24$4.02▼$15.10$347.38M2.091.85 million shs1.18 million shsIRWDIronwood Pharmaceuticals$0.57-8.7%$0.98$0.53▼$7.11$91.64M0.372.58 million shs5.06 million shsRIGLRigel Pharmaceuticals$18.95-4.0%$18.42$7.48▼$29.82$338.67M1.34217,173 shs269,431 shsXOMAXOMA$24.85-1.0%$22.52$18.35▼$35.00$297.38M0.8930,762 shs15,672 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent BioSolutions-1.08%-3.83%+28.39%-17.32%+27.49%IRWDIronwood Pharmaceuticals-8.68%-0.65%-26.65%-68.80%-91.27%RIGLRigel Pharmaceuticals-3.95%-4.44%+4.35%-5.67%+105.44%XOMAXOMA-1.04%-7.93%+6.47%+5.65%-1.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEBSEmergent BioSolutions4.4028 of 5 stars3.53.00.04.62.42.51.3IRWDIronwood Pharmaceuticals4.5586 of 5 stars4.14.00.03.42.60.81.9RIGLRigel Pharmaceuticals2.9473 of 5 stars3.22.00.00.03.61.71.9XOMAXOMA4.0582 of 5 stars3.52.00.03.03.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEBSEmergent BioSolutions 3.00Buy$14.33123.96% UpsideIRWDIronwood Pharmaceuticals 2.13Hold$4.78744.66% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4092.08% UpsideXOMAXOMA 3.00Buy$69.50179.68% UpsideCurrent Analyst Ratings BreakdownLatest IRWD, EBS, RIGL, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.004/17/2025XOMAXOMABenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/16/2025IRWDIronwood PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025IRWDIronwood PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.004/15/2025IRWDIronwood PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $0.704/14/2025IRWDIronwood PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.004/14/2025IRWDIronwood PharmaceuticalsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/1/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/28/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/21/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/19/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent BioSolutions$930.30M0.37$0.72 per share8.92$12.51 per share0.51IRWDIronwood Pharmaceuticals$317.68M0.29N/AN/A($2.21) per share-0.26RIGLRigel Pharmaceuticals$203.08M1.67N/AN/A($1.64) per share-11.55XOMAXOMA$13.05M22.79N/AN/A$7.72 per share3.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent BioSolutions-$760.50M-$2.71N/A3.09N/A-18.55%-9.91%-3.31%8/5/2025 (Estimated)IRWDIronwood Pharmaceuticals-$1.00B-$0.20N/A2.27N/A-0.65%-0.96%0.74%N/ARIGLRigel Pharmaceuticals-$25.09M$2.07135.3718.05N/A2.46%-14.80%3.03%8/5/2025 (Estimated)XOMAXOMA-$40.83M-$1.15N/AN/AN/A-151.34%-24.95%-9.64%8/12/2025 (Estimated)Latest IRWD, EBS, RIGL, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025XOMAXOMA-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million5/7/2025Q1 2025EBSEmergent BioSolutions$0.49$0.71+$0.22$1.19$218.50 million$222.20 million5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 million3/17/2025Q4 2024XOMAXOMA-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million3/4/2025Q4 2024RIGLRigel Pharmaceuticals$0.30$0.80+$0.50$0.80$57.59 million$57.60 million3/3/2025Q4 2024EBSEmergent BioSolutions-$0.35$0.05+$0.40-$0.58$254.67 million$194.70 million2/27/2025Q4 2024IRWDIronwood Pharmaceuticals$0.10$0.02-$0.08$0.02$93.85 million$90.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BioSolutionsN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent BioSolutions1.302.881.47IRWDIronwood PharmaceuticalsN/A3.623.62RIGLRigel PharmaceuticalsN/A1.961.87XOMAXOMA1.287.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent BioSolutions78.40%IRWDIronwood PharmaceuticalsN/ARIGLRigel Pharmaceuticals66.23%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipEBSEmergent BioSolutions3.20%IRWDIronwood Pharmaceuticals12.90%RIGLRigel Pharmaceuticals9.48%XOMAXOMA7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent BioSolutions2,42054.28 million53.53 millionOptionableIRWDIronwood Pharmaceuticals220161.82 million139.38 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.02 millionOptionableXOMAXOMA1011.97 million10.94 millionOptionableIRWD, EBS, RIGL, and XOMA HeadlinesRecent News About These CompaniesInsider Selling: XOMA Co. (NASDAQ:XOMA) CEO Sells 25,637 Shares of StockMay 22 at 7:20 AM | insidertrades.comBvf Partners L. P/Il Sells 392,723 Shares of XOMA Co. (NASDAQ:XOMA) StockMay 21 at 5:40 AM | insidertrades.comMajor Shareholder Sells Massive Chunk of Xoma Stock!May 20, 2025 | tipranks.comStonepine Capital Management LLC Reduces Stock Holdings in XOMA Co. (NASDAQ:XOMA)May 20, 2025 | marketbeat.comLeerink Partnrs Analysts Boost Earnings Estimates for XOMAMay 20, 2025 | marketbeat.comXOMA Royalty First Quarter 2025 Earnings: Beats ExpectationsMay 15, 2025 | finance.yahoo.comXOMA Royalty Reports Strong Q1 2025 ResultsMay 14, 2025 | tipranks.comXOMA Royalty: Q1 Earnings SnapshotMay 13, 2025 | sfgate.comXOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business AchievementsMay 13, 2025 | finance.yahoo.comXOMA Royalty (XOMA) Tops Q1 Earnings and Revenue EstimatesMay 13, 2025 | zacks.comXOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceMay 7, 2025 | globenewswire.comXOMA (XOMA) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comHigh Growth Tech Stocks In The US To Watch April 2025April 22, 2025 | uk.finance.yahoo.comBenchmark Initiates Coverage of XOMA Royalty Corporation - Preferred Stock (XOMAP) with Buy RecommendationApril 18, 2025 | msn.comXoma initiated with a Buy at BenchmarkApril 17, 2025 | markets.businessinsider.comXoma (XOMA) Receives Buy Rating from Benchmark with Promising Growth Forecast | XOMA Stock NewsApril 17, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | gurufocus.comXOMA (XOMA) Sells Kinnate Biopharma Pipeline Assets for Potential $270M | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline Assets | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | globenewswire.comInsider Buying: XOMA Co. (NASDAQ:XOMA) CIO Purchases 2,000 Shares of StockApril 10, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRWD, EBS, RIGL, and XOMA Company DescriptionsEmergent BioSolutions NYSE:EBS$6.40 -0.10 (-1.54%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$6.41 +0.01 (+0.16%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Ironwood Pharmaceuticals NASDAQ:IRWD$0.57 -0.05 (-8.68%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.57 +0.01 (+1.18%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$18.95 -0.78 (-3.95%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.80 -0.15 (-0.77%) As of 05/23/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.XOMA NASDAQ:XOMA$24.85 -0.26 (-1.04%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$24.84 -0.01 (-0.02%) As of 05/23/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
